Boothbay Fund Management
ITCI icon

Boothbay Fund Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Boothbay Fund Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,500
Closed -$1.39M – 1875
2025
Q1 		$1.39M Sell
10,500
-8,200
-44% -$1.02M 0.04% 525
2024
Q4 		$1.56M Buy
+18,700
New +$1.54M 0.04% 510
2024
Q2 		– Sell
-17,600
Closed -$1.22M – 1917
2024
Q1 		$1.22M Buy
+17,600
New +$1.21M 0.02% 689
2021
Q2 		– Sell
-90
Closed -$305K – 2172
2021
Q1 		$305K Sell
90
-15
-14% -$520 0.01% 1182
2020
Q4 		$334K Hold
105
– – 0.01% 910
2020
Q3 		$269K Buy
+105
New +$2.4K 0.02% 842
2020
Q1 		– Sell
-1,505
Closed -$5.17M – 1108
2019
Q4 		$5.17M Buy
1,505
+753
+100% +$9.04K 0.45% 43
2019
Q3 		$562K Sell
752
-1,132
-60% -$10.9K 0.05% 433
2019
Q2 		$2.44M Buy
+1,884
New +$24.2K 0.22% 117

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Huntington National Bank
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Boothbay Fund Management's ITCI Position: Q2 2025 in Review

Boothbay Fund Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 63,819 shares — an estimated $8.42M sold.

Boothbay Fund Management first reported a position in ITCI in Q4 2016 and held it in 11 quarters. The position peaked at $8.42M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Boothbay Fund Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 63,819 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $8.42M.
  • Boothbay Fund Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 11 quarters.
  • Boothbay Fund Management's Intra-Cellular Therapies Inc. position peaked at $8.42M in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.